The most serious side effects of Momelotinib and how to deal with them

Momelotinib As aJAK1/JAK2 inhibitor, it has significant advantages in improvingmyelofibrosis (MF) symptoms and anemia. However, like all targeted drugs, side effects may still occur during its use, some of which may be serious and require high attention from patients and doctors.

In overseas clinical experience, one of the more serious adverse reactions of molotinib is bone marrow suppression, including exacerbation of anemia, thrombocytopenia and leukopenia. If these side effects are not treated in time, they may lead to an increased risk of bleeding, increased risk of infection, and decreased physical strength. In addition, some patients may develop peripheral neuropathy, manifested by numbness, tingling, or burning sensations in the limbs. This damage to the nervous system can affect the quality of daily life in some cases. Individual reports also involve serious infections or liver function abnormalities, so regular monitoring of liver function and blood counts is an important part of safe medication use.

Responses to these side effects include comprehensive hematology and liver function evaluation before treatment and regular reexamination during treatment. Once obvious blood cell decline occurs, intervention can be performed by adjusting the dose, temporarily stopping the drug, or, if necessary, giving erythropoietin, blood transfusion and other supportive treatments. For peripheral neuropathy, early recognition and timely treatment can reduce the risk of irreversible damage. If symptoms are obvious, adjustment of drug dosage or other treatment options can be considered. At the same time, patients should pay attention to preventing infection during medication, maintain good oral and skin hygiene, and avoid contact with known sources of infection.

Overall, the safety of molotinib is within a controllable range, but high-risk adverse reactions must be monitored and managed by professional doctors. Reasonable side effect management can not only reduce the risk of drug discontinuation, but also help patients obtain longer-term treatment benefits.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib